For example, a novel strategy combining STAT3 ASO with TLR9 stimulation (CpG oligonucleotide) has been shown to enhance the anti-tumor immunity and overcome tumor immune tolerance in prostate cancer [184]. Here, STAT3 is linked to neoplasm.